Background: Hidradenitis suppurativa (HS) is a debilitating chronic disease that leads to inflammation and abscess formation in the involved skin, along with a malodorous discharge. Pain is a considerable aspect of HS and significantly impacts quality of life. In addition, HS is significantly associated with depression. A better understanding of contributing factors to depression and pain in patients with HS can identify opportunities to improve care for patients. Objective: To identify factors that contribute to depression and chronic pain in patients with HS. Methods: This is a retrospective chart review of 283 patients seen at dermatology clinics of an academic health center for HS from July 2012 to December 2015. The association between HS and depression and chronic pain was assessed in multivariate models using logistic regression analyses. Results: Patients with a greater number of areas of involvement were more likely to have both chronic pain and depression. Limitations: This is a single-center retrospective chart review with a limited sample size. Conclusion: This study suggests that the extent of disease rather than severity plays a role in reducing the quality of life in HS patients.

1.
Alikhan A, Lynch P, Eisen D: Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539-561.
2.
Shavit E, Dreiher J, Freud T, et al: Psychiatric comorbidities in 3,207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015;29:371-376.
3.
Esmann S, Jemec GB: Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011;91:328-332.
4.
Onderdijk AJ, Van der Zeek HH, Esmann S, et al: Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013, 27:473-478.
5.
Matusiak L, Bieniek A, Szepietowski JC: Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010;90:264-268.
6.
Deckers IE, Kimball AB: The handicap of hidradenitis suppurativa. Dermatol Clin 2016;34:17-22.
7.
von der Werth JM, Jemec GB: Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001;144:809-813.
8.
Saunte DM, Boer J, Stratigos A, et al: Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015;173:1546-1549.
9.
Shahi V, Alikhan A, Vazquez BG, et al: Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County, Minnesota. Dermatology 2014:229:154-158.
10.
Jemec GB, Kimball AB: Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol 2015;73(suppl 1): S4-S7.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.